Open AccessContinuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports
Author(s) -
Memduha Aydın,
Bilge Çetin İlhan,
Saliha Çalışır,
Seda Elçim Yıldırım,
İ̇brahim Eren
Publication year - 2015
Publication title -
therapeutic advances in psychopharmacology
Language(s) - English
Resource type - Journals
eISSN - 2045-1261
pISSN - 2045-1253
DOI - 10.1177/2045125315624063
Subject(s) - leukopenia , clozapine , neutropenia , medicine , lithium (medication) , antipsychotic , schizophrenia (object oriented programming) , psychiatry , intensive care medicine , chemotherapy
Clozapine is a second-generation antipsychotic used for treatment-resistant schizophrenia. Despite its effectiveness, clozapine is largely underused due to serious side effects such as leukopenia or neutropenia. We aimed to review whether to continue, discontinue or rechallenge clozapine treatment after such haematological side effects.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom